Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Sorafenib (Primary) ; Yttrium-90 (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms SIRveNIB
- 22 Apr 2018 Planned End Date changed from 1 Dec 2017 to 31 Jul 2018.
- 22 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 31 Jul 2018.
- 02 Mar 2018 Primary endpoint has not been met. (Overall Survival) as per results published in the Journal of Clinical Oncology